|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Innoviva Inc said on Tuesday activist investor Sarissa Capital Management LP had nominated a slate of directors to replace a majority of the company's board. Innoviva, formerly Theravance Inc, urged shareholders ...
GlaxoSmithKline's Q4 report will be out this coming Wednesday, and investors would be wise to keep track of these key figures when GSK's results are released.
In spite of double-digit percentage projected EPS growth this year, GlaxoSmithKline could face a host of challenges in 2016.